Every material Form 8-K Halozyme has filed with the SEC since November 05, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Halozyme Therapeutics reported third quarter 2026 total revenue of $493 million, representing a 39% increase year-over-year, alongside net income of $247 million. Driven by strong partner product sales and royalty growth, the company raised its full-year 2026 financial guidance ranges for total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS.
Total revenue increased 39% year-over-year to $493 million for the third quarter ended September 30, 2026.
Royalty revenue grew 44% year-over-year to $341 million.
Full-year 2026 total revenue guidance was raised to a range of $1.860 billion to $1.925 billion.
The Dutch patent court issued an injunction against Merck prohibiting the launch of Keytruda Qlex in multiple European markets.
Halozyme Therapeutics elected James Daly to its Board of Directors on September 28, 2026, disclosed in a filing dated September 30, 2026. Mr. Daly was placed in the class of directors with terms ending at the 2029 annual meeting and was not initially assigned to any Board committee.
Board election date: September 28, 2026
Term ends at the company's annual meeting of stockholders in 2029
Not initially assigned to any Board committee
Compensated under the non-employee director program; no related person transactions or election arrangements disclosed
Halozyme Therapeutics completed the sale of $1,500.0 million of 1.50% Convertible Senior Notes due 2033 on September 22, 2026, including $200.0 million from the initial purchasers' option. The company received net proceeds of approximately $1,471.1 million and plans to use part of them to repurchase existing 2027 and 2028 convertible notes, which adds new debt while potentially reducing older debt.
$1,500.0 million aggregate principal of 1.50% Convertible Senior Notes due 2033 sold, including a $200.0 million option exercise
Net proceeds of approximately $1,471.1 million, with $187.5 million used to fund capped call transactions
Expected repurchases of about $217.0 million of 2027 Notes and about $435.5 million of 2028 Notes, including accrued interest
Initial conversion price of approximately $139.84 per share; interest paid semi-annually starting April 1, 2027
Halozyme Therapeutics elected Dannielle Appelhans to its Board of Directors on August 14, 2026, in the class with terms ending at the 2028 annual meeting. She was not initially assigned to any Board committee, and the filing says she will receive compensation under the standard non-employee director program.
Board election effective August 14, 2026; term ends at the 2028 annual meeting of stockholders
Not initially assigned to any Board committee
Compensation follows the non-employee director program (cash retainers, restricted stock and stock options)
Filing states no arrangements or related person transactions with the company
Halozyme reported second quarter 2026 total revenue of $481 million, up 48% from a year earlier, and GAAP diluted EPS of $1.90 versus $1.33. The company raised its full-year 2026 guidance for total revenue, royalty revenue, adjusted EBITDA and non-GAAP diluted EPS, and said it repurchased $333 million of shares in the quarter.
Q2 2026 total revenue $481.0 million vs. $325.7 million in Q2 2025; royalties $307.7 million, up 50%
Net income $229.9 million vs. $165.2 million; GAAP diluted EPS $1.90 vs. $1.33
2026 non-GAAP diluted EPS guidance raised to $8.65-$9.00 from $7.75-$8.25; total revenue guidance raised to $1.835-$1.910 billion
Repurchased 4.8 million shares for $332.8 million at an average price of $69.30 in Q2 2026
Halozyme Therapeutics said on June 30, 2026 that it updated its senior management structure and that Cortney Caudill, Senior Vice President and Chief Operating Officer, is leaving the company. The filing does not give a replacement, a reason for the departure, or any financial effect, so the direct impact on shareholders is unclear from this document alone.
Cortney Caudill, Senior Vice President and Chief Operating Officer, departed the company, as announced June 30, 2026
Halozyme announced an update to its senior management structure on June 30, 2026, without details in the filing
The filing does not name a successor or describe the reason for the departure
Halozyme reported first quarter 2026 total revenue of $376.7 million, up 42% from a year earlier, with royalty revenue of $240.7 million, up 43%. Net income was $150.0 million, compared with $118.1 million, and GAAP diluted EPS was $1.22, compared with $0.93. The company reiterated its 2026 guidance and announced a new $1 billion share repurchase program through December 31, 2028, with at least $400 million expected to be repurchased in 2026.
Q1 2026 total revenue $376.7 million vs. $264.9 million in Q1 2025; royalty revenue $240.7 million vs. $168.2 million
Net income $150.0 million vs. $118.1 million; GAAP diluted EPS $1.22 vs. $0.93; non-GAAP diluted EPS $1.60 vs. $1.11
2026 guidance reiterated: total revenue $1.710 billion to $1.810 billion; non-GAAP diluted EPS $7.75 to $8.25
New share repurchase program of up to $1 billion by December 31, 2028, with at least $400 million expected in 2026
Halozyme appointed Darren Snellgrove, currently Vice President, Investor Relations at Johnson & Johnson, as Chief Financial Officer effective June 8, 2026. Interim CFO David Ramsay will move to an advisory role during a brief transition period. The filing discloses a $670,000 base salary, a bonus target of 50% of salary, and new-hire equity awards with a total grant date value of $7.2 million.
Start date is June 8, 2026; he will report to President and CEO Helen Torley.
Base salary of $670,000 and a bonus target of 50% of base salary, prorated in 2026.
New-hire equity totals $7.2 million: $3.2 million in RSUs and $4.0 million in stock options, plus a $350,000 sign-on cash bonus.
Previously CFO of Johnson & Johnson's Pharmaceutical sector from August 2021 to May 2025.
Halozyme Therapeutics appointed David Ramsay as interim Chief Financial Officer, effective March 23, 2026, while it continues its search for a permanent CFO. Ramsay previously served as the company's CFO from 2003 to 2009 and from 2013 to 2015, and the filing describes his pay and equity grants for the interim role.
Ramsay will receive a monthly salary of $50,000 as interim CFO.
He will receive 10,000 restricted stock units vesting June 30, 2026, if he remains employed through that date.
If he is still interim CFO on July 1, 2026, he will receive an additional 2,500 RSUs.
The company has engaged an executive search firm for a permanent CFO, and Ramsay will serve until one is appointed.
Halozyme reported fourth-quarter 2025 total revenue of $451.8 million, up 52% from a year earlier, but a net loss of $141.6 million, which included $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition. For full-year 2025, total revenue rose 38% to $1.4 billion, and the company reiterated its 2026 guidance for total revenue of $1.710 billion to $1.810 billion and non-GAAP diluted EPS of $7.75 to $8.25.
Q4 2025 total revenue was $451.8 million versus $298.0 million in Q4 2024; royalties were $258.0 million, up 51%.
Q4 2025 net loss was $141.6 million versus net income of $137.0 million a year earlier; GAAP diluted loss was $1.20 per share.
Full-year 2025 total revenue was $1,396.6 million, up 38%, with royalty revenue of $867.8 million, up 52%.
2026 guidance reiterated: total revenue of $1.710 billion to $1.810 billion and non-GAAP diluted EPS of $7.75 to $8.25, last updated January 28, 2026.
Halozyme raised its 2026 financial guidance on January 28, 2026, with total revenue now expected at $1,710 million to $1,810 million, up from $1,430 million to $1,530 million. The company also gave preliminary, unaudited 2025 total revenue of $1,385 million to $1,400 million and disclosed its acquisition of Surf Bio, which carries up to $400 million in total consideration.
2026 royalty revenue guidance raised to $1,130 million-$1,170 million from $900 million-$940 million
2026 non-GAAP diluted EPS guidance raised to $7.75-$8.25 from $6.50-$7.00, including about $60 million of Hypercon and Surf Bio investment not in prior guidance
Surf Bio acquired for an upfront payment of $300 million, plus up to $100 million in milestone payments
Preliminary 2025 royalty revenue estimated at $865 million-$870 million, with 51% to 52% year-over-year growth
Halozyme's Compensation Committee approved a one-time performance-based restricted stock unit grant to CEO Dr. Helen Torley on December 4, 2025, with a grant date fair value of $10 million. The shares vest only if the company's average share price reaches set levels over a four-year period and Torley remains employed through the fourth anniversary of the grant. The award ties a large part of her pay to sustained share price gains.
Grant approved December 4, 2025 under the 2021 Stock Plan; grant date fair value of $10 million
Vesting ranges from 50% to 200% of target, based on average share price hitting $115, $130, $145 or $170
Shares that become eligible must still vest through the fourth anniversary of the grant date; voluntary resignation or retirement before then forfeits performance-based vested shares
Full award agreement to be filed as an exhibit to the 10-K for fiscal year ending December 31, 2025
Halozyme Therapeutics elected James Lang to its Board of Directors on December 4, 2025, with a term ending at the 2027 annual meeting. He was not initially assigned to any board committee, and the filing states there are no related person transactions or arrangements tied to his election.
James Lang elected to the Board of Directors on December 4, 2025
Term ends at the Company's annual meeting of stockholders in 2027
Not initially assigned to any Board committee
Compensated under the standard non-employee director program, described in the 2025 proxy statement
Halozyme said Chief Financial Officer Nicole LaBrosse will stay in the role until the earliest of a new CFO's hiring, March 30, 2026, or an earlier date the company sets, and then leave for a new professional opportunity. Under a Transition and Release Agreement dated November 18, 2025, she is eligible for severance and equity and benefit treatment tied to a termination without cause, which shareholders can review in the company's 10-K for 2025.
CFO Nicole LaBrosse will serve until the earliest of a new CFO being hired, March 30, 2026, or an earlier date set by the company
Transition and Release Agreement dated November 18, 2025, conditioned on her compliance and a release of claims
Benefits include a 2025 annual bonus at 120% of target and severance equal to base salary, plus a pro-rated 2026 target bonus if she separates in 2026
Health coverage under COBRA paid by the company for one year after the separation date; full agreement to be filed with the 10-K for 2025
Halozyme completed the sale of $1,500.0 million of convertible senior notes due 2031 and 2032, with net proceeds of about $1.47 billion. The company used part of the proceeds to repurchase existing convertible notes for about $1.020 billion in cash and to fund about $182.7 million of capped call transactions, with the remainder for general corporate purposes.
Total principal of $1,500.0 million: $750.0 million of 0% notes due 2031 and $750.0 million of 0.875% notes due 2032, including $100.0 million of each from the initial purchasers' option
Net proceeds of about $1.47 billion; about $1.020 billion paid in cash to repurchase 0.25% notes due 2027 and 1.00% notes due 2028, including accrued interest
Initial conversion price of about $87.20 per share; the 2032 notes pay interest semi-annually at 0.875% beginning May 15, 2026
Halozyme proposed offering $650 million of convertible senior notes due 2031 and $650 million due 2032, with an option for up to $100 million more of each. The company also amended its credit agreement, extending the revolving facility to November 5, 2030 and raising total commitments to $750 million, with $0 currently drawn. The proceeds are partly earmarked for repurchasing existing 2027 and 2028 convertible notes, which adds debt while refinancing part of the existing convertible debt.
Proposed offering: $650 million of 2031 notes and $650 million of 2032 notes, plus a 13-day option for up to $100 million more of each series
Revolving credit facility commitments increased to $750 million and maturity extended to November 5, 2030, with no outstanding borrowings as of November 5, 2025
Net proceeds partly used for capped call transactions and privately negotiated repurchases of 0.25% notes due 2027 and 1.00% notes due 2028
Offering is subject to market conditions and pricing terms were not yet set in the filing
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Halozyme filing is on SEC EDGAR ↗. 8-K briefs of other companies →